Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Xi Wen Bi"'
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The association between chemotherapy-induced leukopenia (CIL) and survival for patients with early breast cancer (EBC) is not known. We investigated the relationship between different grades of CIL and survival in patients with EB
Externí odkaz:
https://doaj.org/article/2f0d8ceda28e4f829e6a23b4c55785f7
Autor:
Zhang-Zan Huang, Wen Wen, Xin Hua, Chen-Ge Song, Xi-Wen Bi, Jia-Jia Huang, Wen Xia, Zhong-Yu Yuan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundA higher ratio of pretreatment C-reactive protein/albumin ratio (CAR) is associated with poor prognosis in nasopharyngeal carcinoma (NPC), and Epstein–Barr virus (EBV) DNA level is known to not only participate in the occurrence of nasoph
Externí odkaz:
https://doaj.org/article/06cdc4a6687b49978417acd663340a71
Publikováno v:
Cancer Communications, Vol 38, Iss 1, Pp 1-10 (2018)
Abstract Background Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma often resistant to chemotherapy. Serum level of soluble IL-2 receptor α (IL-2Rα) is elevated in NKTCL patients and correlates significantly with
Externí odkaz:
https://doaj.org/article/347979613dbe49548b626c03f143d9d1
Autor:
Shigeru Imoto, Kun Wang, Xi-wen Bi, Guangyu Liu, Young-Hyuck Im, Seock-Ah Im, Sung Hoon Sim, Takayuki Ueno, Manabu Futamura, Masakazu Toi, Yasuhiro Fujiwara, Sung Gwe Ahn, Jeong Eon Lee, Yeon Hee Park, Shintaro Takao, Mari Saito Oba, Yuko Kitagawa, Masahiko Nishiyama
Publikováno v:
Breast Cancer. 30:412-423
Autor:
Zhang-Zan Huang, Xin Hua, Chen-Ge Song, Wen Xia, Xi-Wen Bi, Zhong-Yu Yuan, Zhen-Yu He, Jia-Jia Huang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Systemic inflammation score (SIS) has been verified as a novel prognostic indicator in several cancer types. However, its prognostic value in breast cancer remains unknown. Furthermore, a nomogram based on SIS is yet to be constructed for
Externí odkaz:
https://doaj.org/article/735feb79eec14d9786e3a4a0456884e6
Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma
Autor:
Xue-wen Zhang, Xi-wen Bi, Pan-pan Liu, Ze-long Liu, Man Nie, Hang Yang, De-xin Lei, Yi Xia, Wen-qi Jiang, Wei-an Zeng
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive lymphoma with a dismal prognosis, and novel therapeutic targets are urgently needed. Programmed death-ligand 1 (PD-L1) has become a promising therapeutic target for various can
Externí odkaz:
https://doaj.org/article/214067872a314b7da2c130f57eea120f
Autor:
Pan‐pan Liu, Ke‐feng Wang, Jie‐tian Jin, Xi‐wen Bi, Peng Sun, Yu Wang, Hang Yang, Zhi‐ming Li, Wen‐qi Jiang, Yi Xia
Publikováno v:
Cancer Medicine, Vol 7, Iss 5, Pp 1845-1851 (2018)
Abstract Primary breast diffuse large B‐cell lymphoma (PB‐DLBCL) is an uncommon extranodal non‐Hodgkin's lymphoma (NHL), which was traditionally treated with anthracycline‐containing regimens followed by consolidative radiation therapy (RT) t
Externí odkaz:
https://doaj.org/article/d9e8b2da38c74639a9394229dd5bdab7
Autor:
Xi-wen Bi, Hua Wang, Wen-wen Zhang, Jing-hua Wang, Wen-jian Liu, Zhong-jun Xia, Hui-qiang Huang, Wen-qi Jiang, Yu-jing Zhang, Liang Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-12 (2016)
Abstract Background Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal, especially for advanced-stage or relapsed diseases. Programmed cell death recep
Externí odkaz:
https://doaj.org/article/6d8ba534587b4011b112f1e51a60483f
Autor:
Zhong-Yu Yuan, Jia-Jia Huang, Shu-Sen Wang, Yong-Yi Zhong, Xin An, Cong Xue, Kui-Kui Jiang, Ruo-Xi Hong, Wen Xia, Ying Guo, Fei Xu, Xin-Mei Liu, Heng Huang, An-Qing Zhang, Le-Hong Zhang, Yuan-Qi Zhang, Zhi-Yong Wu, Ying Lin, Yan-Xia Shi, Jian-Li Zhao, Xi-Wen Bi, Xin Hua
Supplementary Data from Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a46e9bd87871ba34c28979f9372747
https://doi.org/10.1158/1078-0432.22486484
https://doi.org/10.1158/1078-0432.22486484
Autor:
Zhong-Yu Yuan, Jia-Jia Huang, Shu-Sen Wang, Yong-Yi Zhong, Xin An, Cong Xue, Kui-Kui Jiang, Ruo-Xi Hong, Wen Xia, Ying Guo, Fei Xu, Xin-Mei Liu, Heng Huang, An-Qing Zhang, Le-Hong Zhang, Yuan-Qi Zhang, Zhi-Yong Wu, Ying Lin, Yan-Xia Shi, Jian-Li Zhao, Xi-Wen Bi, Xin Hua
Purpose:There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205f3466ab97670a784948795a62ab3a
https://doi.org/10.1158/1078-0432.c.6532331
https://doi.org/10.1158/1078-0432.c.6532331